Member Info for researcher1

no way is it a 5-year wait Sec - within one year there will be sufficient contracts to justify this MCAP, not including the IP, which as we know is certainly worth billions ...

jakey, you are mistaken, it's not jam tomorrow. Angle is now the frontrunner in a truly huge market - simply a question of when everyone catches on - the ovarian results should provide a big jump start - you'd be foolish to be at nominal until at least after that.

come on guys this is a non-discussion - have you worked out the effect of share dilution during that period? didn't think so....

that said, the U.S. tends to be more appreciative.....let's see.

if all the articles had mentioned Parsortix, the SP would be in a different stratum by now....

a moat that took an incredibly long time to dig.... which is suddenly a fantastic bonus.

ok, will check out those small companies...thanks

I hope that's the case - there's always been a sense of treacle-wading with Angle.

looks to have been a torrid year on GROW - what's the deal?

ha, fair point Sang - but I don't agree on the mentality comment - I want Parsortix used as widely and as soon as possible (at least two friends could have been saved, potentially) so am happy to look at acceleration options.

will take a look Sang, thanks - (also thank goodness we got out of 4D). I am definitely not an Angle flipper! (still buying in fact), but Abbott for sure have their beady eyes on the company, and I for one don't mind the idea of Parsortix being given a rocket-boost and global roll-out. (Perhaps we'd be offered some Abbott shares?) I'm keener on seeing the technology flourish than stay blindly loyal to the Angle name...

a tad disingenuous Bojo. Abbott (or whoever) are already perfectly aware of what is on offer in Parsortix, especially post-FDA. The question for them is when to jump, the sooner the cheaper...

why muted market reaction to this diversification I wonder?

Certainly with you miavoce, but emerald has a point about it being a small contract. The key takeaway for me is that it was signed in one day and there is an orderly queue forming - Abbott will be taking note.

and yet it is curiously predictable.....

time to quit the whinging - are Abbott watching?

Jan 26:

Abbott CEO Robert Ford didn't exactly show all of his cards during the company's latest earnings call, but he did hint that there may be some merger and acquisition (M&A) activity in 2022.

During the question-and-answer portion of the fourth-quarter 2021 earnings call on Wednesday, Vijay Kumar, a medtech analyst at Evercore, estimated that Abbott has somewhere north of $40 billion worth of capacity on the balance sheet, conservatively. Ford agreed that yes, Abbott does have plenty of capacity for M&A.

"We've generated a lot of strong cash flow, and quite frankly, it's been a meaningful step-up in that cash flow over the last 1.5 years or so," Ford said. "...We're in a great position now to be able to look at that."

Kumar noted that liquid biopsy and cancer screening diagnostics represents a massive market opportunity, and he asked Ford if that might be an area of interest, given Abbott's leadership position in other corners of the diagnostics market.

"Devices and diagnostics, I will say, are the areas that we're looking at more carefully," Ford said. "... The areas that you referenced are areas that we would be interested in looking at."

I know what you mean Brex. I have traded some and taken some profit to throw a bit of cash at some projects, but more than 60% remains in the share (indeed more like 65% as of this morning) because I believe in the huge long-term future Angle has. Question is how long will it take? the longer it takes the more people die unnecessarily. Let's hope big Pharma see sense and come in with joint deals and upfront payments...

morning Brex. Doesn't appear to me he's doing himself much good atm. AN has big option awards when the SP reaches £4 and set his goal as 2023 for those, so we'll see....

a three-bagging dog for me so far hdd, woof woof!

ha